Evidence Grade A — Regulatory approved. 442 published studies. 62 registered clinical trials.
Medically reviewed by a licensed medical professional
Loading...
Pramlintide (sold as Symlin) is an injectable medication that replaces amylin — a hormone your pancreas normally releases alongside insulin after every meal. In people with diabetes (especially type 1), amylin production is reduced or absent. Pramlintide fills this gap by slowing digestion, reducing appetite, and preventing inappropriate blood sugar spikes after eating. It is the only approved amylin-based treatment.
Pramlintide is also known by these brand and alternate names:
442 published studies: 351 human, 28 animal, 23 in-vitro, 172 reviews
Pramlintide is marketed as Symlin (approved March 2005) and remains the only approved amylin-based treatment. It is used alongside mealtime insulin in both type 1 and type 2 diabetes. Clinical trials showed modest blood sugar improvements (HbA1c reductions of 0.2–0.6%) and approximately 2.3 kg of weight loss — less dramatic than GLP-1 treatments but meaningful as an add-on therapy.
Symlin carries a boxed warning for severe hypoglycaemia, particularly when combined with insulin, and requires careful dose adjustment. Practical uptake has been limited by the need for separate injections at each meal alongside existing insulin injections. Despite its modest clinical impact, pramlintide remains the only medication that addresses the amylin deficiency in diabetes, filling a distinct biological role that GLP-1 treatments do not cover.
Every time your pancreas releases insulin after a meal, it also releases a companion hormone called amylin. In people with diabetes, amylin production is reduced or absent (especially in type 1 diabetes). Pramlintide replaces this missing hormone. It slows stomach emptying so food is absorbed more gradually, tells the brain you are full to reduce overeating, and suppresses the inappropriate release of glucagon (a hormone that raises blood sugar) after meals. These three effects work alongside insulin to smooth out the blood sugar spikes that follow eating.
Clinical trials showed modest blood sugar improvements (HbA1c reductions of 0.2-0.6%) and approximately 2.3 kg of weight loss when added to insulin therapy. These results are less dramatic than GLP-1 medications, and the requirement for additional injections at every meal — on top of existing insulin injections — has been a major practical barrier. Symlin carries a boxed warning for severe hypoglycaemia when combined with insulin, requiring careful dose adjustment. Despite its limited commercial success, the amylin pathway is now experiencing a resurgence of interest. Cagrilintide, a next-generation long-acting amylin analogue from Novo Nordisk, is being studied in combination with semaglutide (as CagriSema) — a combination that could potentially validate the amylin approach in a way pramlintide's inconvenient dosing never could.
PeptideTrace tracks 62 registered clinical trials for Pramlintide sourced from ClinicalTrials.gov.
Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans
Amylin-Induced Migraine Attacks Without Aura
Hypersensitivity to Amylin in Post-Traumatic Headache
Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide
The Role of Amylin in Bone Metabolism
FDA ORIG 1
FDA SUPPL 6
FDA SUPPL 10
FDA SUPPL 20
FDA SUPPL 7
FDA SUPPL 16
FDA SUPPL 23
FDA SUPPL 25
FDA SUPPL 24
FDA SUPPL 26
FDA SUPPL 28
Pramlintide is a 37-amino-acid synthetic analogue of human amylin (islet amyloid polypeptide, IAPP), a peptide hormone co-secreted with insulin from pancreatic β-cells. Three proline substitutions at positions 25, 28, and 29 replace the native sequence to prevent amyloid fibril formation and aggregation, conferring pharmaceutical stability.
Pramlintide activates amylin receptors, which are heterodimeric complexes of the calcitonin receptor (CTR) with receptor activity-modifying proteins (RAMPs 1, 2, or 3). This is a completely distinct receptor system from GLP-1. Pramlintide produces three physiological effects: (1) slowed gastric emptying, (2) suppression of postprandial glucagon secretion from α-cells, and (3) centrally mediated satiety signaling in the area postrema. Critically, pramlintide does NOT stimulate insulin secretion—it complements insulin therapy rather than replacing it.
Pramlintide is marketed as Symlin (approved March 16, 2005) as adjunct to mealtime insulin in both type 1 and type 2 diabetes. Clinical trials demonstrated HbA1c reductions of 0.2–0.6% versus placebo with weight loss of approximately 2.3 kg—modest compared to GLP-1 RAs. Symlin carries a black box warning for the risk of severe insulin-induced hypoglycemia, requiring a mandatory 50% reduction in mealtime insulin dose at initiation. The drug requires separate injections from insulin at each meal.
Linaclotide is marketed as Linzess (approved August 2012). It is taken as a daily oral capsule on an empty stomach, at least 30 minutes before the first meal. The recommended dose is 290 mcg for IBS-C and 72 or 145 mcg for chronic constipation. In clinical trials, approximately 34% of IBS-C patients met the composite improvement endpoint compared to 17% on placebo. Diarrhoea is the most common side effect (approximately 20%) and the leading reason for discontinuation. Linaclotide has a boxed warning against use in children under 6 years due to deaths in young mice, though no such events have been reported in humans. It competes with plecanatide (which targets the same pathway) and other IBS-C treatments.
Elamipretide (Forzinity) was approved by the FDA for Barth syndrome based on the TAZPOWER trial. The randomised crossover phase (12 patients) did not meet its primary endpoints, but the open-label extension (168 weeks) demonstrated durable improvements in walking distance and muscle strength that formed the basis for approval. Barth syndrome affects approximately 1 in 300,000–400,000 births. A larger Phase III trial in primary mitochondrial myopathy (218 patients, MMPOWER-3) did not meet its primary endpoint, and the drug was not approved for that broader indication. Elamipretide remains approved exclusively for Barth syndrome. See also SS-31 (#158) for the research compound context.
Glucagon has been available as an emergency injection since the 1960s and remains the standard rescue treatment for severe hypoglycaemia. Recent innovation has focused on making it easier to administer in emergencies. Baqsimi, approved in 2019, was the first needle-free option as a nasal powder. Gvoke, also approved in 2019, eliminated the need to mix and reconstitute the medication before injection — a significant advance since severe hypoglycaemia often impairs the ability to follow complex preparation steps. Dasiglucagon (Zegalogue), a next-generation stable liquid glucagon approved in 2021, further improved on the convenience of rescue administration. Beyond emergency rescue, glucagon's receptor is now a major research target — dual and triple agonists combining glucagon receptor activity with GLP-1 (such as survodutide and retatrutide) are in advanced clinical trials for obesity and metabolic disease.
Comparisons
Evidence Reviews
Timelines
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
